Literature DB >> 21551320

Expression of Trop2 cell surface glycoprotein in normal and tumor tissues: potential implications as a cancer therapeutic target.

Lara P Stepan1, Esther S Trueblood, Kari Hale, John Babcook, Luis Borges, Claire L Sutherland.   

Abstract

Trop2 is a cell-surface glycoprotein reported to be overexpressed in various types of adenocarcinomas with minimal expression in normal tissues. Recent findings that Trop2 expression correlates with tumor aggressiveness have increased interest in Trop2 as a potential target for cancer immunotherapy. The goal of this study was to extensively evaluate Trop2 expression at the transcript and protein levels in normal and tumor tissues. It was determined that Trop2 is overexpressed on some carcinomas relative to the corresponding normal tissue. However, in human and mouse, Trop2 is highly expressed at both the transcript and protein levels on several essential normal tissues. The findings suggest that the development of therapeutic agents to target Trop2 may require strategies that target Trop2 on malignant tissues in order to minimize potential toxicities to essential normal tissues that also express high levels of Trop2.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21551320      PMCID: PMC3201164          DOI: 10.1369/0022155411410430

Source DB:  PubMed          Journal:  J Histochem Cytochem        ISSN: 0022-1554            Impact factor:   2.479


  30 in total

1.  Cloning of the murine TROP2 gene: conservation of a PIP2-binding sequence in the cytoplasmic domain of TROP-2.

Authors:  T El Sewedy; M Fornaro; S Alberti
Journal:  Int J Cancer       Date:  1998-01-19       Impact factor: 7.396

2.  Immunoanatomic dissection of the human urinary tract by monoclonal antibodies.

Authors:  C Cordon-Cardo; N H Bander; Y Fradet; C L Finstad; W F Whitmore; K O Lloyd; H F Oettgen; M R Melamed; L J Old
Journal:  J Histochem Cytochem       Date:  1984-10       Impact factor: 2.479

3.  Reactivity of CO17-1A and B72.3 in benign and malignant pancreatic diseases.

Authors:  Y Takiyama; M A Tempero; H Takasaki; M Onda; R Tsuchiya; M Büchler; M Ness; D Colcher; J Schlom; P M Pour
Journal:  Hum Pathol       Date:  1989-09       Impact factor: 3.466

4.  Identification of the gene responsible for gelatinous drop-like corneal dystrophy.

Authors:  M Tsujikawa; H Kurahashi; T Tanaka; K Nishida; Y Shimomura; Y Tano; Y Nakamura
Journal:  Nat Genet       Date:  1999-04       Impact factor: 38.330

5.  Tumor-associated calcium signal transducer 2 is required for the proper subcellular localization of claudin 1 and 7: implications in the pathogenesis of gelatinous drop-like corneal dystrophy.

Authors:  Mina Nakatsukasa; Satoshi Kawasaki; Kenta Yamasaki; Hideki Fukuoka; Akira Matsuda; Motokazu Tsujikawa; Hidetoshi Tanioka; Maho Nagata-Takaoka; Junji Hamuro; Shigeru Kinoshita
Journal:  Am J Pathol       Date:  2010-07-22       Impact factor: 4.307

6.  ING-1, a monoclonal antibody targeting Ep-CAM in patients with advanced adenocarcinomas.

Authors:  Johann S de Bono; Anthony W Tolcher; Andre Forero; Gertrude F A Vanhove; Chris Takimoto; Robert J Bauer; Lisa A Hammond; Amita Patnaik; Mark L White; Sui Shen; Muhammad B Khazaeli; Eric K Rowinsky; Albert F LoBuglio
Journal:  Clin Cancer Res       Date:  2004-11-15       Impact factor: 12.531

7.  Gelatinous drop-like dystrophy. A form of primary corneal amyloidosis.

Authors:  F L Weber; J Babel
Journal:  Arch Ophthalmol       Date:  1980-01

8.  Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients.

Authors:  Eliana Bignotti; Paola Todeschini; Stefano Calza; Marcella Falchetti; Maria Ravanini; Renata A Tassi; Antonella Ravaggi; Elisabetta Bandiera; Chiara Romani; Laura Zanotti; Germana Tognon; Franco E Odicino; Fabio Facchetti; Sergio Pecorelli; Alessandro D Santin
Journal:  Eur J Cancer       Date:  2010-01-08       Impact factor: 9.162

9.  Cloning of the gene encoding Trop-2, a cell-surface glycoprotein expressed by human carcinomas.

Authors:  M Fornaro; R Dell'Arciprete; M Stella; C Bucci; M Nutini; M G Capri; S Alberti
Journal:  Int J Cancer       Date:  1995-09-04       Impact factor: 7.396

10.  Characterization of human ovarian carcinoma-associated antigens defined by novel monoclonal antibodies with tumor-restricted specificity.

Authors:  S Miotti; S Canevari; S Ménard; D Mezzanzanica; G Porro; S M Pupa; M Regazzoni; E Tagliabue; M I Colnaghi
Journal:  Int J Cancer       Date:  1987-03-15       Impact factor: 7.396

View more
  44 in total

1.  Chemotherapy agents-induced immunoresistance in lung cancer cells could be reversed by trop-2 inhibition in vitro and in vivo by interaction with MAPK signaling pathway.

Authors:  Xi Wang; Min Long; Ke Dong; Fang Lin; Yuanyuan Weng; Yongri Ouyang; Li Liu; Junxia Wei; Xi Chen; Ting He; Hui-Zhong Zhang
Journal:  Cancer Biol Ther       Date:  2013-09-04       Impact factor: 4.742

2.  The diagnostic value of TROP-2, SLP-2 and CD56 expression in papillary thyroid carcinoma.

Authors:  Xueyang Yang; Yifang Hu; He Shi; Chengzhou Zhang; Zhixiao Wang; Xiaoyun Liu; Huanhuan Chen; Lijuan Zhang; Dai Cui
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-06-27       Impact factor: 2.503

3.  TNF-α promotes colon cancer cell migration and invasion by upregulating TROP-2.

Authors:  Peng Zhao; Zhongtao Zhang
Journal:  Oncol Lett       Date:  2018-01-05       Impact factor: 2.967

4.  Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.

Authors:  Aditya Bardia; Ingrid A Mayer; Jennifer R Diamond; Rebecca L Moroose; Steven J Isakoff; Alexander N Starodub; Nikita C Shah; Joyce O'Shaughnessy; Kevin Kalinsky; Michael Guarino; Vandana Abramson; Dejan Juric; Sara M Tolaney; Jordan Berlin; Wells A Messersmith; Allyson J Ocean; William A Wegener; Pius Maliakal; Robert M Sharkey; Serengulam V Govindan; David M Goldenberg; Linda T Vahdat
Journal:  J Clin Oncol       Date:  2017-03-14       Impact factor: 44.544

5.  Trop2 gene: a novel target for cervical cancer treatment.

Authors:  Xiaoqi Liu; Siqi Li; Faping Yi
Journal:  J Cancer Res Clin Oncol       Date:  2014-05-10       Impact factor: 4.553

6.  A phase 1, dose-escalation study of PF-06664178, an anti-Trop-2/Aur0101 antibody-drug conjugate in patients with advanced or metastatic solid tumors.

Authors:  Gentry T King; Keith D Eaton; Brandon R Beagle; Christopher J Zopf; Gilbert Y Wong; Heike I Krupka; Steven Y Hua; Wells A Messersmith; Anthony B El-Khoueiry
Journal:  Invest New Drugs       Date:  2018-01-15       Impact factor: 3.850

Review 7.  Sacituzumab govitecan: antibody-drug conjugate in triple-negative breast cancer and other solid tumors.

Authors:  K M Fenn; K Kalinsky
Journal:  Drugs Today (Barc)       Date:  2019-09       Impact factor: 2.245

8.  Novel therapies in urothelial carcinoma: a biomarker-driven approach.

Authors:  G Iyer; J E Rosenberg
Journal:  Ann Oncol       Date:  2018-12-01       Impact factor: 32.976

9.  Comparison of extravillous trophoblast cells derived from human embryonic stem cells and from first trimester human placentas.

Authors:  B P Telugu; K Adachi; J M Schlitt; T Ezashi; D J Schust; R M Roberts; L C Schulz
Journal:  Placenta       Date:  2013-04-28       Impact factor: 3.481

10.  The Role of TROP2 in BCC and Cutaneous SCC: A Clinical and Immunohistochemical Study.

Authors:  Azza Gaber Antar Farag; Hala Said El-Rebey; Mohamed Abd El-Moneim Shoeib; Shimaa Mohammed Ahmed El-Fiky; Mustafa Elsayed Elshaib; Amal Farid Mostafa
Journal:  Clin Cosmet Investig Dermatol       Date:  2021-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.